U.S. markets closed
  • S&P Futures

    4,159.50
    -5.25 (-0.13%)
     
  • Dow Futures

    33,985.00
    -31.00 (-0.09%)
     
  • Nasdaq Futures

    13,905.25
    -14.00 (-0.10%)
     
  • Russell 2000 Futures

    2,230.00
    -8.40 (-0.38%)
     
  • Crude Oil

    61.12
    -0.23 (-0.37%)
     
  • Gold

    1,793.70
    +0.60 (+0.03%)
     
  • Silver

    26.58
    +0.01 (+0.06%)
     
  • EUR/USD

    1.2042
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.5640
    +0.0020 (+0.13%)
     
  • Vix

    17.50
    -1.18 (-6.32%)
     
  • GBP/USD

    1.3939
    +0.0007 (+0.05%)
     
  • USD/JPY

    108.0100
    -0.0330 (-0.03%)
     
  • BTC-USD

    53,506.31
    -2,698.73 (-4.80%)
     
  • CMC Crypto 200

    1,232.21
    -30.75 (-2.43%)
     
  • FTSE 100

    6,895.29
    +35.42 (+0.52%)
     
  • Nikkei 225

    29,099.93
    +591.38 (+2.07%)
     

Flexion Therapeutics' (NASDAQ:FLXN) Shareholders Are Down 46% On Their Shares

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) shareholders should be happy to see the share price up 27% in the last month. But that doesn't change the fact that the returns over the last three years have been less than pleasing. Truth be told the share price declined 46% in three years and that return, Dear Reader, falls short of what you could have got from passive investing with an index fund.

Check out our latest analysis for Flexion Therapeutics

Flexion Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling Flexion Therapeutics stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

While the broader market gained around 18% in the last year, Flexion Therapeutics shareholders lost 24%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Flexion Therapeutics you should be aware of.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.